Results 21 to 30 of about 410,903 (309)

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

open access: yesTumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway

open access: yesTumor Biology, 2017
Gallbladder cancer has poor prognosis and limited therapeutic options. Arctigenin, a representative dibenzylbutyrolactone lignan, occurs in a variety of plants.
Mingdi Zhang   +11 more
doaj   +1 more source

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population

open access: yesBalkan Medical Journal, 2017
Aims: Epidermal growth factor receptor mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors.
Gaye Güler Tezel   +3 more
doaj   +1 more source

Differential activity of 2-methylene-19-nor vitamin D analogs on growth factor gene expression in rhino mouse skin and comparison to all-trans retinoic acid. [PDF]

open access: yesPLoS ONE, 2017
While all 2-methylene-19-nor analogs of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) tested produce an increase in epidermal thickness in the rhino mouse, only a subset reduce utricle size (comedolysis).
Jamie M Ahrens   +5 more
doaj   +1 more source

The urine as a diagnostic key for a homozygous EGFR mutation [PDF]

open access: yesRevista Portuguesa de Nefrologia e Hipertensão, 2022
Primary inherited epidermal growth factor receptor defects have recently been described in severe inflammatory skin disease and diarrhoea case reports. We describe two case reports of female preterm newborns of Roma consanguineous parents who presented ...
Mafalda Casinhas Santos   +4 more
doaj   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

open access: yes, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp   +7 more
core   +1 more source

The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model

open access: yes, 2012
One challenge of squamous cell carcinoma of the head and neck (SCCHN) chemotherapy is a small percentage of tumor cells that arrest in the G0 phase of the cell cycle and are thus not affected by chemotherapy. This could be one reason for tumor recurrence
Arnoldner, Christoph   +6 more
core   +1 more source

The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer [PDF]

open access: yes, 2009
The levels of expression of the four receptors and eleven ligands composing the Epidermal Growth Factor family were measured using immunohistochemical staining in one hundred cases of breast cancer. All of the family were expressed to some degree in some
McIntyre, Emmet   +4 more
core   +1 more source

THE PROGNOSTIC ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION IN COMPLETELY RESECTED AMPULLARY ADENOCARCINOMA

open access: yes, 2023
The aim of this study is to make a differential diagnosis and prognosis of the amp-ullary adenocarcinoma subtypes. We also investigated the role of prognostic mark-ers PD-1 and PD-L1, and epidermal growth factor receptor (EGFR). Local or locally advanced
Safiye Aktas   +19 more
core   +1 more source

Potency and stability of C terminal truncated human epidermal growth factor

open access: yes, 2000
INTRODUCTION: Epidermal growth factor (EGF) is normally present as EGF(1-53). A variety of C terminal truncated forms have been used in preliminary trials for treating gastrointestinal injury but their relative potency and stability when used in a ...
Lakhoo, K   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy